ReviewDrugs in context2023
Non-small-cell lung cancer: how to manage
Review in Drugs in context, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The safety and efficacy of binimetinib for lung cancer: a systematic review.BMC pulmonary medicine · 2024Pooled it
- Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies.Journal of thoracic disease · 2026Review
- The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand?International journal of general medicine · 2026Review
- Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.Journal of the National Cancer Institute · 2025Article
- A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC.Scientific reports · 2025Article
- Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer withAmerican journal of cancer research · 2025Article
- MicroRNAs and lung cancer: overview of essential pathways and somatic mutations in cancer progression.Frontiers in oncology · 2025Review
- Association between genetic mutations in lung adenocarcinoma and adult body mass index: a retrospective cohort study.Frontiers in oncology · 2025Article
- Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects.Multidisciplinary respiratory medicine · 2024Article
- Exploring immunotherapy efficacy in non-small cell lung cancer patients withTranslational lung cancer research · 2024Article
- The evolving treatment landscape for BRAF-mutated non-small cell lung cancer.Translational lung cancer research · 2024Article
- A MEK inhibitor arrests the cell cycle of human conjunctival fibroblasts and improves the outcome of glaucoma filtration surgery.Scientific reports · 2024Article
- Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.International journal of molecular sciences · 2024Review
- Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials.Frontiers in oncology · 2024Review
- Successful dabrafenib and trametinib combination therapy in a patient with recurrentRespirology case reports · 2024Article
- Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.Future oncology (London, England) · 2024Article
- Current status of molecular diagnostics for lung cancer.Exploration of targeted anti-tumor therapy · 2024Review
- Review
- Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.Current oncology (Toronto, Ont.) · 2023Article
- The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks.Drugs in context · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.